Nintedanib Ratiopharm

Nintedanib, the active ingredient in Nintedanib Ratiopharm, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of idiopathic pulmonary fibrosis and systemic sclerosis‑associated interstitial lung disease in adult patients.

GNH USA supplies Nintedanib Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets EU quality standards and is manufactured under GMP conditions.

Nintedanib is used to treat fibrotic lung disorders by targeting pathways that drive fibroblast activity.

Idiopathic pulmonary fibrosis: slows disease progression and preserves lung function. Systemic sclerosis‑associated interstitial lung disease: reduces decline in forced vital capacity. Progressive fibrosing interstitial lung disease: decreases rate of lung function loss in eligible patients.

Nintedanib may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Nausea - Diarrhea - Abdominal pain - Decreased appetite - Vomiting - Elevated liver enzymes (ALT/AST)

Serious or Rare Side Effects: - Severe liver injury (hepatotoxicity) - Major bleeding events - Arterial thromboembolic events - Hypertension - Gastrointestinal perforations - Severe skin reactions (e.g., Stevens‑Johnson syndrome)

Before initiating therapy, clinicians should assess baseline health status and monitor for specific risks.

Liver function monitoring: assess baseline and periodic liver enzymes. Bleeding risk: avoid concomitant anticoagulants unless necessary. Cardiovascular assessment: monitor blood pressure and signs of arterial thrombosis. Gastrointestinal health: watch for signs of perforation, especially in patients with diverticulitis. Pregnancy and lactation: use only if potential benefit justifies risk; data are limited. Store at ambient temperature: keep below 25 °C, protect from moisture and light in original container.

Nintedanib can interact with several drug classes; some combinations should be avoided while others require close monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase nintedanib exposure. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding risk. - P‑glycoprotein inhibitors (e.g., verapamil): may raise plasma levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Antiplatelet agents (e.g., aspirin, clopidogrel): monitor for bleeding. - Diuretics: may exacerbate dehydration and renal effects.